The tool was created daklinza corporation Bristol Myers Squibb and was approved for use in Japan, Canada, Europe, the United States. Its main purpose - combating hepatitis C in combination therapy with other drugs. Assign daklinzu and requiring recovery of liver function abnormalities after suffering a hepatitis.